Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer

Molecular Medicine Reports

Volumn 2, Issue 3, 2009, Pages 477-480

  Kojima, Taiki ^a   Yoshikawa, Kazuhiro ^b   Matsui, Takanori ^a   Kodera, Yasuhiro ^c   Kojima, Hiroshi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CEA; CEA IgM complexes; Colorectal cancer; p53 antibodies; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN M; P53 PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SCREENING; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; PRIMARY TUMOR; SENSITIVITY AND SPECIFICITY;

EID: 69249084072     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000124     Document Type: Article

References (17)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
2. American Cancer Society: Cancer facts and figures. American Cancer Society, Washington, DC, pp1-39, 2000.
3. Winawer SJ: A quarter century of colorectal cancer screening: progress and prospects. J Clin Oncol 19 (Suppl. 18): S6-S12, 2001.
4. Ransohoff DF and Sandler RS: Clinical practice. Screening for colorectal cancer. N Engl J Med 346: 40-44, 2002.
5. Thomas FI, David FR, Steven HI, Barry AT and Michael ER: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average risk population. N Engl J Med 351: 2704-2714, 2004.
6. Lieberman DA and Weiss DG: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345: 355-360, 2001.
7. Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 104: 66-73, 1986.
8. Shimada H, Ochiai T, Nomura F and Japan p53 Antibody Research Group: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors: a multi-institutional analysis by the Japan p53 Antibody Research Group. Cancer 97: 682-689, 2003. (Pubitemid 36125846)
9. Levine A, Momand J and Finlay C: The p53 tumor suppressor gene. Nature 351: 453-455, 1991.
10. Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
11. Castaldi F, Marino M, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M and Fassina G: Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers 20: 204-208, 2005. (Pubitemid 43103615)
12. Christian F, Friedel K, Peter K, Suse H, Wolfram J and Jochen RK: CEA-containing immune complexes in sera of patients with colorectal and breast cancer: analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 26: 180-184, 1988.
13. Palombo G, Verdoiva A and Gassina G: Affinity purification of immunoglobulin M using a novel synthetic ligand. J Chromatogr B 715: 137-145, 1998. (Pubitemid 28403606)
14. Dalgaard P: Introductory statistics with R. Springer-Verlag, New York Inc., 2002.
15. Yahui S, Jing S, Huachong M, et al: Diagnosis of gastric cancer using decision tree classification of mass spectra data. Cancer Sci 98: 37-43, 2007.
16. Kojima T, Yoshikawa K, Matsui T, Kodera Y and Kojima H: Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. J Surg Sci (In press).
17. Gorelik E, Landsittel DP, Marrangoni AM, Mondugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB and Lokshin AE: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 981-987, 2005. (Pubitemid 40478567)